Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) was upgraded by analysts at Raymond James to a "moderate buy" rating.
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Oppenheimer Holdings Inc. from $48.00 to $52.00. They now have an "outperform" rating on the stock.
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Raymond James from $51.00 to $56.00. They now have an "outperform" rating on the stock.